*NOTE: The thick consistency is normal. We do not use an ethanol base as it can become hepatoxic with prolonged use.
RAD-140 is an investigational selective androgen receptor modulator (SARM) developed as a future substitute of exogenous Testosterone replacement therapy (TRT)
RAD140 was discovered and initially developed by Radius Health, Inc. (RDUS). The first-in-human study was initiated in 2017 in patients with breast cancer. It was licensed to Ellipses Pharmaceuticals in 2020.
Interestingly RAD-140 reduces sex hormone binding globulin (SHBG), which has the consequence of increasing free-circulating testosterone counts. Not only does this bode well for increasing lean muscle mass and reducing body fat levels, clinical trials demonstrated that a higher free testosterone index was associated with better scores on visual and verbal memory, visuospatial functioning, visual-motor scanning and a reduced rate of longitudinal decline in visual memory. Therefore, RAD-140 becomes a potent anti-neurodegenerative adjunct therapy for those suffering Alzheimers.
RAD-140 has also been studied in patients with breast cancer. RAD140 is a potent AR agonist in breast cancer cells with a distinct mechanism of action, including the AR-mediated repression of ESR1. It inhibits the growth of multiple AR/ER+ breast cancer PDX models as a single agent, and in combination with palbociclib.
RAD-140 is typically used as a lean bulking agent, or for those seeking an alternative compound to testosterone in order to circumvent the side effects typically associated with that drug.